0001062993-22-009836.txt : 20220405 0001062993-22-009836.hdr.sgml : 20220405 20220405195418 ACCESSION NUMBER: 0001062993-22-009836 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220401 FILED AS OF DATE: 20220405 DATE AS OF CHANGE: 20220405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Adda Nathalie CENTRAL INDEX KEY: 0001646976 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35839 FILM NUMBER: 22809039 MAIL ADDRESS: STREET 1: C/O ENANTA PHARMACEUTICALS, INC. STREET 2: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001177648 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617 607 0800 MAIL ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2022-04-01 0001177648 ENANTA PHARMACEUTICALS INC ENTA 0001646976 Adda Nathalie C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 0 1 0 0 Sr. VP & Chief Medical Officer Common Stock 2022-04-01 4 M 0 16000 31.42 A 50982 D Common Stock 2022-04-01 4 M 0 31664 30.00 A 82646 D Common Stock 2022-04-01 4 M 0 2895 48.52 A 85541 D Common Stock 2022-04-01 4 S 0 8299 70.75 D 77242 D Common Stock 2022-04-01 4 S 0 42260 71.32 D 34982 D Common Stock 2022-04-04 4 M 0 6285 48.52 A 41267 D Common Stock 2022-04-04 4 M 0 9625 43.57 A 50892 D Common Stock 2022-04-04 4 M 0 16875 63.35 A 67767 D Common Stock 2022-04-04 4 S 0 2500 70.56 D 65267 D Common Stock 2022-04-04 4 S 0 18076 71.71 D 47191 D Common Stock 2022-04-04 4 S 0 3200 72.65 D 43991 D Common Stock 2022-04-04 4 S 0 9009 73.42 D 34982 D Stock Option (Right to Buy) 31.42 2022-04-01 4 M 0 16000 0 D 2025-11-20 Common Stock 16000 0 D Stock Option (Right to Buy) 30.00 2022-04-01 4 M 0 31664 0 D 2026-11-18 Common Stock 31664 0 D Stock Option (Right to Buy) 48.52 2022-04-01 4 M 0 2895 0 D 2027-11-17 Common Stock 2895 6285 D Stock Option (Right to Buy) 48.52 2022-04-04 4 M 0 6285 0 D 2027-11-17 Common Stock 6285 0 D Stock Option (Right to Buy) 43.57 2022-04-04 4 M 0 9625 0 D 2030-11-20 Common Stock 9625 21175 D Stock Option (Right to Buy) 63.35 2022-04-04 4 M 0 16875 0 D 2029-11-18 Common Stock 16875 13125 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.00, inclusive. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.00, inclusive. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.06 to $70.99, inclusive. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.91, inclusive. 100% of the shares subject to the option are fully vested and exercisable. The option, representing a right to purchase a total of 30,800 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020). The option, representing a right to purchase a total of 30,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019). The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7 above. /s/ Nathaniel S. Gardiner as attorney-in-fact 2022-04-05